We are live on ! Find out more
PAP

Persistent Asset Partners Portfolio holdings

AUM $268M
1-Year Est. Return 158.98%
This Fund
S&P 500
This Quarter Est. Return
+35.4%
1 Year Est. Return
+158.98%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$268M
AUM Growth
+$45.6M
Cap. Flow
+$18.2M
Cap. Flow %
6.78%
Top 10 Hldgs %
33.7%
Holding
508
New
146
Increased
78
Reduced
73
Closed
186

Top Buys

1
TSEM icon
Tower Semiconductor
TSEM
+$9.09M
2
LITE icon
Lumentum
LITE
+$8.24M
3
GLW icon
Corning
GLW
+$6.49M
4
INTC icon
Intel
INTC
+$5.94M
5
ALAB icon
Astera Labs
ALAB
+$4.77M

Top Sells

1
CNC icon
Centene
CNC
+$9.07M
2
MOH icon
Molina Healthcare
MOH
+$8.9M
3
ELV icon
Elevance Health
ELV
+$8.08M
4
BTSG icon
BrightSpring Health Services
BTSG
+$3.52M
5
TERN
Terns Pharmaceuticals
TERN
+$2.78M

Sector Composition

1 Technology 44.62%
2 Healthcare 29.67%
3 Financials 9.04%
4 Consumer Discretionary 3.92%
5 Energy 3.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLTE
351
Belite Bio
BLTE
$6.02B
– –
-673
Closed -$108K
BSX icon
352
Boston Scientific
BSX
$65.4B
– –
-8,748
Closed -$834K
CAH icon
353
Cardinal Health
CAH
$53.5B
– –
-5,695
Closed -$1.17M
CAT icon
354
CALL
Caterpillar
CAT
$405B
– –
-9
Closed -$72
CDTX
355
DELISTED
Cidara Therapeutics
CDTX
– –
-4,704
Closed -$1.04M
CDXS icon
356
Codexis
CDXS
$204M
– –
-27,813
Closed -$45.3K
CFG icon
357
Citizens Financial Group
CFG
$30.6B
– –
-11,696
Closed -$683K
CHE icon
358
Chemed
CHE
$6.77B
– –
-337
Closed -$144K
CNC icon
359
Centene
CNC
$32.8B
– –
-220,530
Closed -$9.07M
CNTA
360
CALL
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-57
Closed -$15.5K
CNTA
361
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-43,266
Closed -$1.08M
CORT icon
362
PUT
Corcept Therapeutics
CORT
$9.72B
– –
-362
Closed -$633K
CRVS icon
363
PUT
Corvus Pharmaceuticals
CRVS
$1.25B
– –
-142
Closed -$7.51K
CSTL icon
364
Castle Biosciences
CSTL
$733M
– –
-2,463
Closed -$95.8K
CVE icon
365
Cenovus Energy
CVE
$52.1B
– –
-35,975
Closed -$609K
CVS icon
366
CVS Health
CVS
$137B
– –
-22,431
Closed -$1.78M
CYTK icon
367
Cytokinetics
CYTK
$10.9B
– –
-3,214
Closed -$204K
DNLI icon
368
Denali Therapeutics
DNLI
$3.7B
– –
-5,670
Closed -$93.6K
DSGN icon
369
Design Therapeutics
DSGN
$785M
– –
-34,989
Closed -$328K
EDIT icon
370
CALL
Editas Medicine
EDIT
$457M
– –
-862
Closed -$34
EDSA icon
371
Edesa Biotech
EDSA
$63.6M
– –
-12,319
Closed -$17.5K
EHAB
372
DELISTED
Enhabit
EHAB
– –
-227,806
Closed -$2.1M
EHTH icon
373
eHealth
EHTH
$47.3M
– –
-97,606
Closed -$449K
ELV icon
374
Elevance Health
ELV
$80.9B
– –
-23,039
Closed -$8.08M
FBK icon
375
FB Financial Corp
FBK
$3B
– –
-13,565
Closed -$757K
13 14
15
16 17

Similar funds

VC
VarCov Co Darien, Connecticut $268M AUM
AL
AIP LLC New York $268M AUM 40.4% 1-Year Est. Return
FC
Foursixthree Capital New York $268M AUM 115.24% 1-Year Est. Return
NF
Nvest Financial Portsmouth, New Hampshire $268M AUM 22.87% 1-Year Est. Return
PF
Prosperitas Financial Valencia, California $268M AUM 32.64% 1-Year Est. Return
UI
Untitled Investments New York $269M AUM 11.35% 1-Year Est. Return
SSWM
Strait & Sound Wealth Management San Francisco, California $269M AUM 22.03% 1-Year Est. Return
AC
Applied Capital Little Rock, Arkansas $268M AUM 16.92% 1-Year Est. Return

Persistent Asset Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Persistent Asset Partners held 508 positions worth $268M, up 20% from $223M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Persistent Asset Partners deployed $18.2M of net new capital in Q1 2026, opening 146 new positions and adding to 78 existing holdings. Its largest new stake was Tower Semiconductor: 67,608 shares worth $11.9M.

By sector, the portfolio is most concentrated in Technology at 45% of assets, up from 14% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was Terns Pharmaceuticals, an estimated $2.78M trimmed.

  • Persistent Asset Partners's largest Q1 2026 buy was Tower Semiconductor: 67,608 shares worth $11.9M.
  • Persistent Asset Partners added most to Lumentum in Q1 2026, an estimated $8.24M increase.
  • Persistent Asset Partners's biggest Q1 2026 reduction was Terns Pharmaceuticals, cutting an estimated $2.78M.
  • Persistent Asset Partners fully exited Centene in Q1 2026, selling an estimated $9.07M.
  • Persistent Asset Partners's ten largest holdings make up 34% of its $268M portfolio in Q1 2026.
  • Persistent Asset Partners opened 146 new positions and closed 186 in Q1 2026.
  • Persistent Asset Partners's portfolio value rose 20% quarter-over-quarter to $268M.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.